Literature DB >> 10822368

Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia.

L Stepanova1, G Yang, F DeMayo, T M Wheeler, M Finegold, T C Thompson, J W Harper.   

Abstract

The Cdc37 gene encodes a 50 kDa protein which targets intrinsically unstable oncoprotein kinases such as Cdk4, Raf-1, and src to the molecular chaperone Hsp90. This activity is thought to play an important role in the establishment of signaling pathways controlling cell proliferation. The budding yeast Cdc37 homolog is required for cell division and mammalian Cdc37 is expressed in proliferative zones during embryonic development and in adult tissues, consistent with a positive role in proliferation. Here we report that human prostatic tumors, neoplasias and certain pre-malignant lesions display increased Cdc37 expression, suggesting an important and early role for Cdc37 in prostatic transformation. To test the consequences of increased Cdc37 levels, transgenic mice expressing Cdc37 in the prostate were generated. These mice displayed a wide range of growth-related abnormalities including prostatic epithelial cell hyperplasia and dysplasia. These data suggest that the expression of Cdc37 may promote inappropriate proliferation and may be an important early step in the development of human prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10822368     DOI: 10.1038/sj.onc.1203561

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  39 in total

1.  Cdc37 is essential for chromosome segregation and cytokinesis in higher eukaryotes.

Authors:  Bodo M H Lange; Elena Rebollo; Andrea Herold; Cayetano González
Journal:  EMBO J       Date:  2002-10-15       Impact factor: 11.598

Review 2.  Cdc37 goes beyond Hsp90 and kinases.

Authors:  Morag MacLean; Didier Picard
Journal:  Cell Stress Chaperones       Date:  2003       Impact factor: 3.667

3.  CK2 controls multiple protein kinases by phosphorylating a kinase-targeting molecular chaperone, Cdc37.

Authors:  Yoshihiko Miyata; Eisuke Nishida
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

4.  Split Renilla luciferase protein fragment-assisted complementation (SRL-PFAC) to characterize Hsp90-Cdc37 complex and identify critical residues in protein/protein interactions.

Authors:  Yiqun Jiang; Denzil Bernard; Yanke Yu; Yehua Xie; Tao Zhang; Yanyan Li; Joseph P Burnett; Xueqi Fu; Shaomeng Wang; Duxin Sun
Journal:  J Biol Chem       Date:  2010-04-22       Impact factor: 5.157

5.  The C-terminal domain of human Cdc37 studied by solution NMR.

Authors:  Ziming Zhang; Dimitra Keramisanou; Amit Dudhat; Michael Paré; Ioannis Gelis
Journal:  J Biomol NMR       Date:  2015-09-24       Impact factor: 2.835

6.  Structure of an Hsp90-Cdc37-Cdk4 complex.

Authors:  Cara K Vaughan; Ulrich Gohlke; Frank Sobott; Valerie M Good; Maruf M U Ali; Chrisostomos Prodromou; Carol V Robinson; Helen R Saibil; Laurence H Pearl
Journal:  Mol Cell       Date:  2006-09-01       Impact factor: 17.970

7.  The role of stress proteins in prostate cancer.

Authors:  Alan So; Boris Hadaschik; Richard Sowery; Martin Gleave
Journal:  Curr Genomics       Date:  2007-06       Impact factor: 2.236

Review 8.  Cdc37 as a co-chaperone to Hsp90.

Authors:  Stuart K Calderwood
Journal:  Subcell Biochem       Date:  2015

9.  Canonical and kinase activity-independent mechanisms for extracellular signal-regulated kinase 5 (ERK5) nuclear translocation require dissociation of Hsp90 from the ERK5-Cdc37 complex.

Authors:  Tatiana Erazo; Ana Moreno; Gerard Ruiz-Babot; Arantza Rodríguez-Asiain; Nicholas A Morrice; Josep Espadamala; Jose R Bayascas; Nestor Gómez; Jose M Lizcano
Journal:  Mol Cell Biol       Date:  2013-02-19       Impact factor: 4.272

10.  Fission yeast Cdc37 is required for multiple cell cycle functions.

Authors:  P K Westwood; I V Martin; P A Fantes
Journal:  Mol Genet Genomics       Date:  2003-12-03       Impact factor: 3.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.